You are here

Rigel Pharma Scraps Skin Disease Drug

JAK/SYK inhibitor fails phase II trial (October 24)

An investigational dermatologic agent, R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did not meet the primary endpoint in a recently completed phase II clinical study. The primary endpoint was the proportion of patients who achieved at least a 50% decrease from baseline in the total combined erythema and scaling score of all treated lesions at week 4.

In light of these findings, the drug’s developer (Rigel Pharmaceuticals) has decided not to pursue this indication further with R333. The decision comes about 2 months after the company stopped the development of an asthma drug.

R333 is a topical Janus kinase/spleen tyrosine kinase (JAK/SYK) inhibitor.

Sources: Rigel Pharmaceuticals; October 24, 2014; and Reuters; October 24, 2013.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs